HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU’s Microplastic Restriction Hints At Precautionary Creep – Cosmetics Europe

Executive Summary

The European cosmetics industry sees ECHA’s recommended microplastic restriction as evidence of the precautionary principle’s growing ascendancy, a trend that is only likely to deepen amid the “green wave” spreading across Europe. The US, meanwhile, has been going in an opposite direction, posing potentially significant trade implications, Cosmetics Europe’s Director-General John Chave suggests.

You may also be interested in...



Microplastic, Macro-Headache: European Cosmetics Industry Dismayed By Early Signs In Restriction Process

Initial committee debate as to whether ECHA’s proposed microplastic restriction meets regulatory threshold requirements for substances posing “unacceptable risk” was shorter-lived than industry advocates anticipated, following the contentious proposal’s issuance at the end of January. Cosmetics Europe head John Chave provides an update on the process and discusses next steps.

ECHA Targets Cosmetics, Leave-On And Rinse-Off Alike, With Proposed Microplastics Ban

Manufacturers of rinse-off and leave-on cosmetics would have four years and six years, respectively, to comply with ECHA’s proposed restriction on intentionally added microplastics, efforts that ECHA estimates would cost industry around $1.1bn and $7.4bn over 20 years. Microbeads in rinse-off exfoliating/cleansing cosmetics, largely phased out already, would be banned without delay.

US Interim Funding Bill Gets Biden’s Signature; Window Narrows For Cosmetics, Dietary Supplement Legislation

Passed by the US House and signed into law on 30 September, the Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023, avoids a partial government shutdown and furloughs in FDA user-fee programs. Policy riders stripped from the legislation, including for cosmetics and dietary supplement regulatory changes, could still find their way into a final FY 2023 spending omnibus.

Latest News
See All
UsernamePublicRestriction

Register

RS149012

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel